Can Topical Estrogen Be Used with Other Hormones?

Why Combining Hormones Is Often the Standard of Care

Topical estrogen alone is rarely the full picture for most women going through perimenopause or menopause. Adding one or more additional hormones addresses symptom domains that estrogen cannot cover on its own. The standard of care for a woman with an intact uterus is combined estrogen-progestogen therapy, and many women also benefit from adjunctive testosterone or DHEA for symptoms like low libido, fatigue, or vaginal atrophy.

The Endometrial Protection Rationale

Estrogen stimulates growth of the uterine lining. Without a progestogen to oppose that growth, prolonged estrogen exposure raises the risk of endometrial hyperplasia and endometrial cancer. A 1995 analysis published in the New England England Journal of Medicine found that women using unopposed estrogen for more than 10 years had a relative risk of endometrial cancer of approximately 9.5 compared with non-users [1]. Adding a progestogen reduces that risk to levels seen in women not using any hormone therapy.

This is why the North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement states: "Progestogen is required for endometrial protection in women with a uterus who use systemic estrogen" [2].

When Estrogen Alone Is Appropriate

Women who have had a hysterectomy do not have a uterus to protect. For them, estrogen-only therapy (including topical estrogen) is the appropriate regimen, and adding a progestogen offers no documented uterine benefit while adding its own risk profile. The decision to add testosterone or DHEA in this group is still individualized based on symptoms.

Topical Estrogen Combined with Progesterone or Progestogens

This is the most common combination in clinical practice. The progestogen can be delivered orally, transdermally, vaginally, or via an intrauterine device. Each route interacts differently with the topical estradiol.

Oral Micronized Progesterone (Prometrium)

Oral micronized progesterone 200 mg taken at bedtime for 12 days per month (cyclic) or 100 mg nightly (continuous) is one of the best-studied pairings with transdermal or topical estradiol. The Kronos Early Estrogen Prevention Study (KEEPS, N=727) used 0.05 mg/day transdermal estradiol patches plus 200 mg oral micronized progesterone and demonstrated favorable cardiovascular and cognitive safety signals when therapy was initiated within six years of menopause [3].

Oral micronized progesterone does not substantially alter transdermal estradiol absorption. The two can be used on the same day without timing concerns.

Transdermal Progesterone Creams

Over-the-counter progesterone creams exist, but their systemic absorption is low and variable. A Cochrane review confirmed that topical progesterone creams do not reliably produce serum progesterone levels adequate for endometrial protection [4]. Prescription transdermal progesterone gels (such as Crinone) are used primarily for fertility support rather than long-term HRT.

Clinicians at HealthRX generally do not recommend OTC progesterone creams as the sole progestogen for endometrial protection in women on systemic topical estrogen. Prescription oral or vaginal progesterone is more reliable.

Levonorgestrel-Releasing IUD (Mirena)

The Mirena IUD releases 20 mcg of levonorgestrel per day locally into the uterine cavity. This provides effective endometrial protection without raising systemic progestogen levels significantly, which may reduce progestogen-related side effects like bloating, mood changes, and breast tenderness. Combined with topical estradiol gel or spray, this represents an increasingly popular regimen, particularly for women who are sensitive to systemic progestogens.

A 2018 study in the journal Maturitas confirmed that the levonorgestrel IUD combined with estradiol gel maintained endometrial safety over 12 months with favorable symptom control [5].

Combination Timing and Skin Site Separation

When applying multiple topical hormones, applying them to different body areas and separating application times by at least 30 minutes reduces the chance of one preparation diluting the other. Standard practice is to apply estradiol gel or spray to the arm or thigh, and to apply any separate topical testosterone or DHEA preparation to a different site such as the inner forearm or abdomen.

Topical Estrogen Combined with Testosterone

Why Women Are Prescribed Testosterone

Low sexual desire affecting quality of life is the primary clinical indication for adding testosterone to a woman's HRT regimen. Testosterone is not FDA-approved for women in the United States, but the Endocrine Society's 2014 Clinical Practice Guideline recommends short-term testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD) when other causes have been excluded [6].

Doses Used in Women

Female testosterone doses are roughly one-tenth to one-twentieth of those used in men. Typical doses are 0.5 to 2 mg of testosterone per day delivered via a transdermal cream or gel, targeting a serum free testosterone level in the upper quartile of the normal female range (approximately 1.5 to 2.5 ng/dL free testosterone). Many clinicians use commercially available male testosterone products at fractionated doses or compounded female-specific testosterone preparations.

Evidence for Testosterone Addition

The APHRODITE trial (N=814) found that a 300-mcg/day testosterone patch significantly improved the frequency of satisfying sexual events and sexual desire scores versus placebo in surgically menopausal women on estrogen therapy, with P<0.0001 for both co-primary endpoints [7]. The 52-week safety data showed no increase in breast cancer incidence or adverse cardiovascular events at this dose.

A 2019 meta-analysis in The Lancet Diabetes and Endocrinology (N=8,480 participants across 36 trials) confirmed testosterone's efficacy for HSDD and reported that physiologic-range testosterone supplementation did not raise cardiometabolic or breast cancer risk versus placebo over the time frames studied [8].

Monitoring When Adding Testosterone

Serum total and free testosterone should be checked at baseline, then at 6 to 8 weeks after initiating therapy, and every 6 months once the dose is stable. Clinicians should also monitor for androgenic side effects: acne, increased body or facial hair, and voice changes. These are dose-dependent and reversible with dose reduction.

Topical Estrogen Combined with DHEA (Prasterone)

What DHEA Does in This Context

DHEA (dehydroepiandrosterone) is a precursor hormone converted locally in tissues to both estrogens and androgens. The FDA approved vaginal prasterone (Intrarosa 6.5 mg nightly vaginal insert) in 2016 specifically for moderate to severe dyspareunia due to vulvovaginal atrophy [9]. Because prasterone acts locally in vaginal tissue, its systemic estrogen and androgen levels remain within postmenopausal reference ranges at the approved dose.

Using DHEA Alongside Systemic Topical Estrogen

A woman using systemic topical estradiol for vasomotor symptoms may also need vaginal DHEA for local atrophy symptoms if the systemic estrogen dose is not high enough to relieve vaginal dryness. These two treatments address different symptom domains and can be prescribed together. Published data do not show a meaningful pharmacokinetic interaction between vaginal prasterone and transdermal estradiol.

Clinicians should document the rationale for using both, since the combination increases total estrogen exposure modestly. Endometrial monitoring frequency may need adjustment.

Oral DHEA Supplementation

Oral DHEA 25 to 50 mg/day is used off-label by some practitioners to support libido, energy, and adrenal function. Oral DHEA does raise systemic estrogen and androgen levels, making careful monitoring essential when combined with topical estrogen. There are no large randomized trials establishing the long-term safety of oral DHEA plus systemic estrogen specifically, so clinical judgment and shared decision-making apply here.

Topical Estrogen Combined with Thyroid Hormones

A Common Clinical Overlap

Many perimenopausal and postmenopausal women are also on thyroid hormone replacement. Estrogen increases thyroid-binding globulin (TBG), which can lower free thyroxine levels and push a previously stable thyroid patient toward hypothyroidism. This effect is more pronounced with oral estrogen than transdermal estrogen because oral estrogen undergoes first-pass hepatic metabolism that strongly stimulates TBG synthesis.

A 2001 study in the Journal of Clinical Endocrinology and Metabolism demonstrated that transdermal estradiol produced significantly smaller increases in TBG compared with oral conjugated equine estrogen, making the transdermal route preferable for women on thyroid hormone replacement [10].

Practical Monitoring Guidance

Any woman on levothyroxine (Synthroid, Tirosint, generic) who starts topical estrogen should have her TSH rechecked at 6 to 8 weeks. A TSH rising above the reference range indicates the levothyroxine dose needs upward adjustment. Typically, this is a modest increase of 12.5 to 25 mcg/day.

Topical Estrogen with Vaginal Estrogen: Is Dual Use Reasonable?

Some women use systemic topical estrogen (estradiol gel, spray, or patch) and still experience persistent vaginal dryness or recurrent urinary tract infections. Adding low-dose vaginal estrogen (estradiol cream 0.5 g two to three times weekly, or the estradiol vaginal ring Estring releasing 7.5 mcg/day) is an accepted clinical practice.

The NAMS position statement notes that low-dose vaginal estrogen used alongside systemic estrogen therapy is appropriate when vaginal symptoms persist, with the acknowledgment that total estrogen exposure increases modestly and progestogen adequacy should be confirmed [2].

Systemic absorption from low-dose vaginal estrogen preparations is minimal. The Estring ring, for example, maintains serum estradiol at approximately 8 to 12 pg/mL, within the postmenopausal reference range, indicating predominantly local action.

Safety Considerations Across All Combinations

The following decision framework organizes the key safety checks a clinician should run before and during any combination topical estrogen regimen.

Before Starting Any Combination

• Confirm uterine status (hysterectomy or intact uterus).
• Obtain baseline serum levels: estradiol, FSH, total testosterone, free testosterone, SHBG, DHEAS, TSH, and a full metabolic panel.
• Screen for contraindications to estrogen: personal history of estrogen-receptor-positive breast cancer, unexplained vaginal bleeding, active thromboembolic disease, or uncontrolled hypertension.
• Confirm the patient has had age-appropriate breast cancer and cervical cancer screening within current guideline intervals.

During Therapy

• Recheck hormone levels at 6 to 8 weeks after any new combination is started or dose is changed.
• Ask about breakthrough bleeding at every visit. Irregular bleeding in a woman on continuous combined therapy after the first 6 months of use warrants endometrial biopsy.
• Monitor blood pressure. Transdermal estrogens are less likely than oral estrogens to raise blood pressure, but monitoring remains appropriate.
• Reassess the regimen at least annually. The NAMS 2022 position statement does not set a mandatory stop date for HRT but advises ongoing benefit-risk reassessment [2].

Breast Cancer Context

The Women's Health Initiative (WHI) estrogen-plus-progestin arm (N=16,608, mean follow-up 5.6 years) reported a hazard ratio of 1.26 for breast cancer with conjugated equine estrogen plus medroxyprogesterone acetate versus placebo [11]. The estrogen-alone arm (N=10,739, mean follow-up 7.2 years) showed a non-significant reduction in breast cancer risk (HR 0.79, P<0.001 for significance not met) in women with prior hysterectomy [11]. This difference between progestogen types matters: micronized progesterone carries a lower breast cancer signal than synthetic progestins in observational data, though head-to-head randomized data are limited.

Compounded Combination Creams: What to Know

Compounded preparations like "bi-est" (estradiol plus estriol) or "tri-est" (estradiol, estrone, estriol) are prescribed by some practitioners to deliver multiple estrogens in a single cream, sometimes alongside progesterone or testosterone in the same preparation. These are not FDA-approved. The FDA has explicitly stated that compounded hormones have not been shown to be safer or more effective than FDA-approved products, and that quality, potency, and sterility cannot be guaranteed to the same standard [12].

If a patient chooses a compounded regimen, they should use a compounding pharmacy that is PCAB-accredited, ensure independent potency testing, and maintain regular serum hormone level monitoring. A 2007 survey found potency variation of up to 68% in some compounded estrogen preparations, underscoring the importance of accreditation and testing.